Full Press Release Details
4D Molecular Therapeutics and Roche Sign Collaboration Agreement for Gene Therapy Vector Discovery and Product Development.
FDMT
4D Molecular Therapeutics and Roche Sign Collaboration Agreement for Gene Therapy Vector Discovery and Product Development
Key Takeaway: 4D Molecular Therapeutics and Roche Sign Collaboration Agreement for Gene Therapy Vector Discovery and Product Development
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+128%
120-day peak, hindsight
Typical move
11.2%
average across 9 past catalysts
Cash runway
~18 mo
Low dilution risk
Lead asset
4D-150 IVT
Phase 3 · Macular Neovascularization Secondary to Age-Related Macular Degeneration